The cancer cachexia syndrome.
The provision of additional calories and protein alone has not been shown to be efficacious in patients with cancer cachexia. Although primary research continues to unravel the complex metabolic derangements and diverse mediator pathways underlying cancer cachexia, the future lies in drugs and neutracenticals that may modulate this altered metabolism and enable conventional nutritional support to effectively replenish vital lean tissue.
Fearon
K C
KC
Professor of Surgical Oncology and Honorary Consultant Surgeon, Department of Clinical and Surgical Sciences(Surgery), The Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
Barber
M D
MD
Moses
A G
AG
D000209:Acute-Phase Proteins / Q000276:immunology; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002100:Cachexia / Q000175:diagnosis / Q000209:etiology* / Q000276:immunology / Q000378:metabolism / Q000628:therapy*; D003131:Combined Modality Therapy; D016207:Cytokines / Q000276:immunology; D005395:Fish Oils / Q000627:therapeutic use; D013502:General Surgery; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D018377:Neurotransmitter Agents / Q000276:immunology; D018529:Nutritional Support / Q000379:methods*; D010166:Palliative Care / Q000379:methods*; D013256:Steroids; D013727:Terminal Care / Q000379:methods*
D000209:Acute-Phase Proteins; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D005395:Fish Oils; D018377:Neurotransmitter Agents; D013256:Steroids